Podcasts about expert panel

Kia ora,Welcome to Wednesday's Economy Watch where we follow the economic events and trends that affect Aotearoa/New Zealand.I'm David Chaston and this is the international edition from Interest.co.nz.And today we lead with news the global economic expansion is losing pace, led by the US.But first up today, the overnight full dairy auction pulled back, and expected, but perhaps not be as much as the derivatives markets suggested. In the end prices were down -1.6% in USD terms and -3.0% in NZD terms on a rising Kiwi dollar. It was a mixed picture across the commodities offered.In the US, the weekly Redbook retail monitor pulled back last week to be 'only' +4.9% higher than the same week a year ago. That is a sharpish dip from the prior week's +6.1% and mid-April's +7.4%. Much of this may be attributable to tariff-tax increases, with sales volumes easing faster now.Meanwhile, April job openings were little-changed but they did come in slightly higher than expected at 7.4 mln. We get the May non-farm payrolls report this Saturday (NZT) and that is expected to show a modest +130,000 rise.Meanwhile April factory orders came in weak, down a sharp -3.7% following the boosted March gain of +3.4%. Between the two months, a slight easing that was setting in since November. From April 2024 these order levels are up +0.6% and that is before accounting for inflation.The US Logistics Managers Index rose, but because inventory costs, warehousing utilisation, and transportation prices all rose at a faster rate, probably not the indicators that help their economy.But the latest RCM/TIPP optimism survey did rise for 'positive' reasons, but only back to levels it was in November after retreating rather sharply from a February high. The tariff-tax staggers may be easing among investors and the surveyors say this indicates US "consumers are closer to optimism".In Canada, Canadians have so heavily altered their travel plans to the US that the duty-free stores at the border seem to be on their knees in what is being called a 'collapse'.In South Korea, the candidate of the more liberal Democratic Party seems to be the winner of Tuesday's snap presidential election. It is a clear break, with voters turning away from the conservative party, who's previous President triggered their constitutional crisis. It's a win for the rule of law. The other main candidate has conceded.In China, they have delivered something of a surprise. The May Caixin China factory PMI unexpectedly dropped to 48.3, down from April's expanding 50.4 and missing market forecasts of a faster expansion (50.6). This was the first contraction in the sector in eight months and the steepest since September 2022. Output shrank alongside a renewed drop in new orders, with foreign sales declining at a faster pace. The official factory PMI came in at 49.5, a small improvement (lesser decline).Eurozone consumer price inflation eased to 1.9% in May, down from 2.2% in April and below market expectations of 2.0%. With inflation under control, that gives the ECB some room to trim interest rates further at their Friday (NZT) review.Globally, the OECD has lowered its economic expansion forecasts as the Trump tariff-taxes bite, and the US an economy they see suffering as much as others from the impact.That is spurring free trade talks among other nations, especially between Australia and the EU.In Australia, their Fair Work Commission's Expert Panel announced the National Minimum Wage and award wages will increase by +3.5% from 1 July 2025, following the 2024-25 Annual Wage Review. That means their National Minimum Wage will increase by +AU$0.85 to AU$24.95 per hour. (NZ$26.90/hr) The New Zealand adult minimum wage is currently $23.50/hr.The UST 10yr yield is now at 4.46%, and unchanged from yesterday.The price of gold will start today at US$3,353/oz, and down -US$22 from yesterday.Oil prices are up +50 USc in the US at just over US$63.50/bbl and the international Brent price is up +US$1 at US$66/bbl.The Kiwi dollar is now at 60.1 USc, a -10 bps dip from yesterday at this time. Against the Aussie we are down -10 bps at just on 92.8 AUc. Against the euro we are unchanged at 52.7 euro cents. That all means our TWI-5 starts today at just on 68.1 and down -10 bps from yesterday.The bitcoin price starts today at US$105,965 and up +1.6% from yesterday. Volatility over the past 24 hours has been modest at just on +/-1.2%.You can get more news affecting the economy in New Zealand from interest.co.nz.Kia ora. I'm David Chaston. And we will do this again tomorrow.

Jack Chambers-Ward gathers an esteemed panel of SEO all-stars: Dawn Anderson, Jono Alderson, Myriam Jessier, and, the birthday boy himself, Chris Green.Together, they discuss the future of search, focusing on key topics such as the impact of AI mode, the evolution of search behaviour, and the transparency of data.Tune in for an insightful discussion from these industry experts about how they are navigating the ever-shifting SEO landscape and what it means for the future of search marketing.Follow Chris:

Gut-Brain Connection: How to Boost Cognitive Health, Prevent Cognitive Decline, and Age with Resilience | Expert Panel Discussion In this powerful episode, Coach Debbie Potts is joined by three trailblazing leaders in gut health, cognitive resilience, and cellular nutrition: Martha Carlin – CEO & Founder of BiotiQuest Dr. William Davis – Cardiologist, author of Super Gut, creator of Gut to Glow Amber Lynn Vitale – Clinical Director at BEAM Minerals Together, we dive deep into the science behind the gut-brain axis, vagus nerve health, and cellular mineral replenishment to help you stay sharp, energized, and resilient as you age.

See omnystudio.com/listener for privacy information.

On today's episode of Women of Impact, host Lisa Bilyeu dives headfirst into the explosive start of the Diddy trial—a case that's sending shockwaves through the world of celebrity, power, and abuse. Joined by criminal analyst Laura Richards and defense attorney Karen Conti, Lisa unpacks the allegations against Sean “Diddy” Combs: abuse, coercion, manipulation, and an alleged pattern of violence going back decades. The trial's centerpiece? Cassie's 35-page lawsuit and a damning hotel hallway video that's impossible to unsee. Is Cassie a gold digger—or a victim finally being heard? Why do so many women's voices go ignored for so long? Our experts break down how coercion and power imbalances keep women trapped, expose the tactics defense teams use to discredit survivors, and share crucial signs to help women avoid the trap in the first place. This is more than a celebrity scandal—it's a pivotal moment for all women. Tune in as we shine a light on the realities of abuse, challenge the legal and cultural systems that enable it, and share tools every woman needs to protect herself. This is just day one of our special series following the Diddy trial on Women of Impact. Join us as we turn outrage into action, and support every woman's right to be heard, believed, and empowered. SHOWNOTES 00:00 Cassie Lawsuit Highlights Power Imbalance 05:11 Music Dream Turned Nightmare 11:02 Unveiling Abuse Patterns and Impact 16:55 Claims of Video Tampering 22:05 Legal Defense Arguments Summarized 26:48 Coercive Control and Celebrity Power 36:08 Menendez Trial Jury Concerns 42:11 "Transformation from Silence to Strength" 48:06 "Supporting Young Women in Crisis" 50:33 "Maintain Financial & Personal Autonomy" 55:32 "Defense Claims Mutuality in Abuse" 01:01:27 "Empowerment Through Aging and Support" 01:05:08 "Controversy and Empowerment in Film" 01:12:22 "Legal Battle: Sean Combs Defense Tactics" 01:17:13 "Wealthy Abusers and Empowerment" FOLLOW KAREN CONTI: Instagram: https://www.instagram.com/karengconti/ Twitter: https://twitter.com/KarenConti FOLLOW DR. ANN BURGESS: Bio at Boston College: https://www.bc.edu/bc-web/schools/connell-school/faculty-research/faculty-directory/ann-burgess.html FOLLOW LAURA RICHARDS: Instagram: https://www.instagram.com/laurarichards999/ Twitter: https://twitter.com/laurarichards99 Website: https://www.laurarichards.co.uk/ CHECK OUT OUR SPONSORS Vital Proteins: Get 20% off by going to https://www.vitalproteins.com and entering promo code WOI at check out.  BIOptimizers: Head to https://bioptimizers.com/impact and use code IMPACT for 10% off.  OneSkin: Get 15% off with code LISA at https://oneskin.co  Shopify: Sign up for your one-dollar-per-month trial period at https://shopify.com/lisa ****************************************************************** LISTEN TO WOMEN OF IMPACT AD FREE + BONUS EPISODES on APPLE PODCASTS:  apple.co/womenofimpact ****************************************************************** FOLLOW LISA: Instagram: https://www.instagram.com/lisabilyeu/ Twitter: https://twitter.com/lisabilyeu YouTube: https://www.youtube.com/womenofimpact Tik Tok: https://www.tiktok.com/@lisa_bilyeu?lang=en Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the FINOS Open Source in Finance webinar series, Karl Moll hosts an engaging panel discussion with Tyler Warden from Sonatype and Aaron Erickson from Nvidia. The topic is 'The Unexpected Risks of AI in Finance,' covering hidden and novel security risks in AI-driven financial systems, the importance of hardware in AI security, and regulatory approaches to AI compliance. The panelists delve into common misconceptions, real-world examples of AI risks, software supply chain issues, and actionable advice for securing AI pipelines. They also discuss the fundamental role of human accountability and the importance of collaboration between security and engineering teams.00:00 Welcome and Introduction03:40 Panelist Introductions05:43 Common Misconceptions in AI Security08:37 Hidden Risks of AI in Finance16:52 Regulatory Approaches to AI Risks23:54 Advice for Compliance Teams30:56 The Importance of Fundamentals in AI31:37 AI's Role in Speeding Up Reaction Times32:56 Building Security into AI Pipelines36:02 Operational Collaboration for AI Security43:07 Designing User-Centric AI Systems48:40 Rapid Fire Q&A on AI Security55:23 Final Thoughts and RecommendationsFind more info about FINOS:On the web: https://www.finos.org Open Source in Finance Forum (OSFF Conference): https://www.finos.org/osff-2025 2024 State of Open Source in Financial Services Download: ⁠https://www.finos.org/state-of-open-source-in-financial-services-2024⁠ FINOS Current Newsletter Here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.finos.org/newsletterLinkedIn: https://www.linkedin.com/company/finosfoundation Twitter: https://twitter.com/FINOSFoundation About FINOSFINOS (The Fintech Open Source Foundation) is a nonprofit whose mission is to foster the adoption of open source, open standards, and collaborative software development practices in financial services. It is the center for open source developers and the financial services industry to build new technology projects that have a lasting impact on business operations. As a regulatory compliant platform, the foundation enables developers from these competing organizations to collaborate on projects with a strong propensity for mutualization. It has enabled codebase contributions from both the buy- and sell-side firms and counts over 50 major financial institutions, fintechs and technology consultancies as part of its membership. FINOS is also part of the Linux Foundation, the largest shared technology organization in the world. Get involved and join FINOS as a Member.

In 2018, ‘toxic' became Oxford's word of the year. You've likely fallen victim to toxic behaviors in different relationships in your life. Even more shocking, is that you've even been toxic at varying times in your life. We all have. Whether the word is overused and completely misunderstood, this episode will help you think through toxic relationships and behaviors that may be costing you more than you know. After this episode, you'll be able to identify some of the relationships that are no longer serving you and start examining the options you have for letting go of toxic people. Learning to set boundaries and identify language that you can use to spot red flags will serve you for many years to come. [ORIGINAL AIR DATE: 8-18-21]. SHOW NOTES: Vilify Toxicity | Don't Vilify Toxic People with Sara Jakes Roberts [2:36] Complainers | Avoid Complaining About Them with Amy Morin [6:30] Vulnerabilities | Be Thoughtful About Sharing Vulnerabilities with Matthew Husssey [12:02] Stand Up | Stand Up For Yourself with Nedra Glover Tawwab [16:12] Empathetic | Reconsider Your Relationship With Them with Lori Gottlieb & Dr. Ramani [19:39] Boundaries | Create Clear Boundaries with Vanessa Van Edwards [24:33] Follow Sara Jakes Roberts: https://sarahjakesroberts.com/ Follow Dr. Ramani: http://doctor-ramani.com/ Follow Amy Morin: https://amymorinlcsw.com/ Follow Matthew Hussey: https://www.howtogettheguy.com/core-confidence/ Follow Nedra Glover Tawwab: https://www.nedratawwab.com/ Follow Lori Gottlieb: https://lorigottlieb.com/ CHECK OUT OUR SPONSORS Vital Proteins: Get 20% off by going to https://www.vitalproteins.com and entering promo code WOI at check out.  BIOptimizers: Head to https://bioptimizers.com/impact and use code IMPACT for 10% off.  OneSkin: Get 15% off with code LISA at https://oneskin.co  Kettle & Fire: Get 20% off at https://kettleandfire.com/lisa with code LISA Netsuite: Download the CFO's Guide to AI and Machine Learning at https://NetSuite.com/women LISTEN TO WOMEN OF IMPACT AD FREE + BONUS EPISODES on APPLE PODCASTS:  apple.co/womenofimpact FOLLOW LISA: Instagram: https://www.instagram.com/lisabilyeu/ Twitter: https://twitter.com/lisabilyeu YouTube: https://www.youtube.com/womenofimpact Tik Tok: https://www.tiktok.com/@lisa_bilyeu?lang=en Learn more about your ad choices. Visit megaphone.fm/adchoices

Diarrhea is one of the more common concerns in emergency medicine worldwide and in the United States, yet we often do not spend enough time understanding the breadth of causes and considerations for this syndrome. Do you know which patients benefit from Zinc? Would you like to review HUS? Can you mixup Oral Rehydration Solution if you needed to? We cover all of this and more in this “code brown” of a chapter! So come, get dirty with Alex and Venk in this truly crappy chapter of Always on EM!   CONTACTS X - @AlwaysOnEM; @VenkBellamkonda YouTube - @AlwaysOnEM; @VenkBellamkonda Instagram – @AlwaysOnEM; @Venk_like_vancomycin; @ASFinch Email - AlwaysOnEM@gmail.com REFERENCES & LINKS Shane AL, Mody RK, Crump JA, Tarr PI, Steiner TS, Kotloff K, Langley JM, Wanke C, Warren CA, Cheng AC, Cantey J, Pickering LK. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis. 2017 Nov 29;65(12):e45-e80. doi: 10.1093/cid/cix669. PMID: 29053792; PMCID: PMC5850553. Gore JI, Surawicz C. Severe acute diarrhea. Gastroenterol Clin North Am. 2003 Dec;32(4):1249-67. doi: 10.1016/s0889-8553(03)00100-6. PMID: 14696306; PMCID: PMC7127018. Freedman SB, van de Kar NCAJ, Tarr PI. Shiga Toxin–Producing Escherichia coli and the Hemolytic–Uremic Syndrome. The New England Journal of Medicine. 2023;389(15):1402-1414. doi:10.1056/NEJMra2108739. Logan C, Beadsworth MB, Beeching NJ. HIV and diarrhoea: what is new? Curr Opin Infect Dis. 2016 Oct;29(5):486-94. doi: 10.1097/QCO.0000000000000305. PMID: 27472290. Chassany O, Michaux A, Bergmann JF. Drug-induced diarrhoea. Drug Saf. 2000 Jan;22(1):53-72. doi: 10.2165/00002018-200022010-00005. PMID: 10647976. Schiller LR. Secretory diarrhea. Curr Gastroenterol Rep. 1999 Oct;1(5):389-97. doi: 10.1007/s11894-999-0020-8. PMID: 10980977. Gong Z, Wang Y. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review. JCO Oncol Pract. 2020 Aug;16(8):453-461. doi: 10.1200/OP.20.00002. Epub 2020 Jun 25. PMID: 32584703. Do C, Evans GJ, DeAguero J, Escobar GP, Lin HC, Wagner B. Dysnatremia in Gastrointestinal Disorders. Front Med (Lausanne). 2022 May 13;9:892265. doi: 10.3389/fmed.2022.892265. PMID: 35646996; PMCID: PMC9136014. Expert Panel on Gastrointestinal Imaging; Chang KJ, Marin D, Kim DH, Fowler KJ, Camacho MA, Cash BD, Garcia EM, Hatten BW, Kambadakone AR, Levy AD, Liu PS, Moreno C, Peterson CM, Pietryga JA, Siegel A, Weinstein S, Carucci LR. ACR Appropriateness Criteria® Suspected Small-Bowel Obstruction. J Am Coll Radiol. 2020 May;17(5S):S305-S314. doi: 10.1016/j.jacr.2020.01.025. PMID: 32370974. Rami Reddy SR, Cappell MS. A Systematic Review of the Clinical Presentation, Diagnosis, and Treatment of Small Bowel Obstruction. Curr Gastroenterol Rep. 2017 Jun;19(6):28. doi: 10.1007/s11894-017-0566-9. PMID: 28439845. Modahl L, Digumarthy SR, Rhea JT, Conn AK, Saini S, Lee SI. Emergency department abdominal computed tomography for nontraumatic abdominal pain: optimizing utilization. J Am Coll Radiol. 2006 Nov;3(11):860-6. doi: 10.1016/j.jacr.2006.05.011. PMID: 17412185. Scheirey CD, Fowler KJ, Therrien JA, et al. ACR Appropriateness Criteria Acute Nonlocalized Abdominal Pain. Journal of the American College of Radiology : JACR. 2018;15(11S):S217-S231. doi:10.1016/j.jacr.2018.09.010. Atia AN, Buchman AL. Oral rehydration solutions in non-cholera diarrhea: a review. Am J Gastroenterol. 2009 Oct;104(10):2596-604; quiz 2605. doi: 10.1038/ajg.2009.329. Epub 2009 Jun 23. PMID: 19550407. Musekiwa A, Volmink J. Oral rehydration salt solution for treating cholera: ≤ 270 mOsm/L solutions vs ≥ 310 mOsm/L solutions. Cochrane Database Syst Rev. 2011 Dec 7;2011(12):CD003754. doi: 10.1002/14651858.CD003754.pub3. PMID: 22161381; PMCID: PMC6532622. Centers for Disease Control and Prevention (CDC). Scombroid fish poisoning associated with tuna steaks--Louisiana and Tennessee, 2006. MMWR Morb Mortal Wkly Rep. 2007 Aug 17;56(32):817-9. PMID: 17703171. Résière D, Florentin J, Mehdaoui H, Mahi Z, Gueye P, Hommel D, Pujo J, NKontcho F, Portecop P, Nevière R, Kallel H, Mégarbane B. Clinical Characteristics of Ciguatera Poisoning in Martinique, French West Indies-A Case Series. Toxins (Basel). 2022 Aug 3;14(8):535. doi: 10.3390/toxins14080535. PMID: 36006197; PMCID: PMC9415704. Centers for Disease Control and Prevention (CDC). Ciguatera fish poisoning--Texas, 1998, and South Carolina, 2004. MMWR Morb Mortal Wkly Rep. 2006 Sep 1;55(34):935-7. PMID: 16943762. Thyroid Inferno EM Blog: https://emblog.mayo.edu/2014/11/01/thyroid-inferno/  Lazzerini M, Wanzira H. Oral zinc for treating diarrhoea in children. Cochrane Database Syst Rev. 2016 Dec 20;12(12):CD005436. doi: 10.1002/14651858.CD005436.pub5. PMID: 27996088; PMCID: PMC5450879. Dhingra U, Kisenge R, Sudfeld CR, Dhingra P, Somji S, Dutta A, Bakari M, Deb S, Devi P, Liu E, Chauhan A, Kumar J, Semwal OP, Aboud S, Bahl R, Ashorn P, Simon J, Duggan CP, Sazawal S, Manji K. Lower-Dose Zinc for Childhood Diarrhea - A Randomized, Multicenter Trial. N Engl J Med. 2020 Sep 24;383(13):1231-1241. doi: 10.1056/NEJMoa1915905. PMID: 32966722; PMCID: PMC7466932. Dalfa RA, El Aish KIA, El Raai M, El Gazaly N, Shatat A. Oral zinc supplementation for children with acute diarrhoea: a quasi-experimental study. Lancet. 2018 Feb 21;391 Suppl 2:S36. doi: 10.1016/S0140-6736(18)30402-1. Epub 2018 Feb 21. PMID: 29553435.   WANT TO WORK AT MAYO? EM Physicians: https://jobs.mayoclinic.org/emergencymedicine EM NP PAs: https://jobs.mayoclinic.org/em-nppa-jobs   Nursing/Techs/PAC: https://jobs.mayoclinic.org/Nursing-Emergency-Medicine EMTs/Paramedics: https://jobs.mayoclinic.org/ambulanceservice All groups above combined into one link: https://jobs.mayoclinic.org/EM-Jobs

Today, we're venturing off the beaten path to explore the lesser-known gems of Greece. Picture yourself wandering through the picturesque streets of Tinos, soaking in the stunning views of Folegandros, and discovering the ancient beauty of Meteora. From the charming towns of Syros to the vibrant culture of Thessaloniki, we'll uncover hidden treasures and authentic experiences. Joining me today are my friends Eva, Anthi, Agnes, and Smaragda. We have such a fun conversation exploring these gems, talking about Greek hospitality, and sharing the heart and soul of this enchanting country.  I hope you enjoy this unique journey through Greece on today's episode of Luxury Travel Insider!  Learn more at www.luxtravelinsider.com   Connect with me on Social: Instagram LinkedIn  

How do you build a community that actually connects—not just scrolls, likes, and disappears?In this special Do The Thing Podcast panel episode, Stacey Lauren brings together seven brilliant women from across industries who've built activated, purpose-driven communities. Together, they unpack the real patterns behind deep connection and consistent engagement—and what most people get wrong when trying to lead a group, grow an audience, or “find their people.”You'll learn:✔️ Why shared transitions matter more than shared interests✔️ The #1 mindset shift that turns passive members into co-leaders✔️ How digital platforms can actually make connection deeper✔️ What community looks like when it runs on purpose, not egoFeaturing:• Jane Stecyk – VP Marketing, Mighty Networks• Nicole Haase – CEO, Modern Prairie• Amanda Black – Founder, Solo Female Traveler Network • Eileen Wilder – Founder of Wild & Free• Christina Rowe – Founder, Women Helping Women Entrepreneurs• Felena Hanson – Founder, Hera Hub• Laura Carney – Author of "My Father's List"Timestamps:00:00 – Stacey's opening: Why “find my people” matters now06:12 – Jane on transitions as the key to belonging12:45 – Amanda on creating courage locally and globally18:05 – Nicole on safety and softness in digital space23:20 – Christina on generosity and platform-sharing28:50 – Felena on scaling support for entrepreneurs34:30 – Eileen on voice, confidence, and virtual energy40:15 – Laura on legacy, loss, and finding connection through action47:00 – Closing reflections and challenge preview

Diagnosis and management of nail unit squamous cell carcinoma: a clinical review by an expert panel.Curtis KL, Amin SP, Jellinek NJ, Knackstedt TJ, Miller CJ, Piraccini BM, Richert B, Rubin AI, Trakatelli MG, Lipner SR. JAAD Reviews. 2024 Dec 31.Evaluation and diagnosis of longitudinal melanonychia: A clinical review by a nail expert group.Ricardo JW, Bellet JS, Jellinek N, Lee D, Miller CJ, Piraccini BM, Richert B, Rubin AI, Lipner SR.Journal of the American Academy of Dermatology. 2025 Feb 27.

How do you build a community that actually connects—not just scrolls, likes, and disappears? In this special Do The Thing Podcast panel episode, Stacey Lauren brings together seven brilliant women from across industries who've built activated, purpose-driven communities.  Together, they unpack the real patterns behind deep connection and consistent engagement—and what most people get wrong when trying to lead a group, grow an audience, or “find their people.” You'll learn: ✔️ Why shared transitions matter more than shared interests ✔️ The #1 mindset shift that turns passive members into co-leaders ✔️ How digital platforms can actually make connection deeper ✔️ What community looks like when it runs on purpose, not ego Featuring: • Jane Stecyk – VP Marketing, Mighty Networks • Nicole Haase – CEO, Modern Prairie • Amanda Black – Founder, Solo Female Traveler Network + Kindred • Eileen Wilder – Virtual Events & Speaker Strategist • Christina Rowe – Founder, Women Helping Women Entrepreneurs • Felena Hanson – Founder, Hera Hub • Laura Carney – Author + Do The Thing Co-Creator Timestamps: 00:00 – Stacey's opening: Why “find my people” matters now 06:12 – Jane on transitions as the key to belonging 12:45 – Amanda on creating courage locally and globally 18:05 – Nicole on safety and softness in digital space 23:20 – Christina on generosity and platform-sharing 28:50 – Felena on scaling support for entrepreneurs 34:30 – Eileen on voice, confidence, and virtual energy 40:15 – Laura on legacy, loss, and finding connection through action 47:00 – Closing reflections and challenge preview You can check it out here:YouTube: https://youtu.be/u54yIydGcNQ Apple Podcasts: https://podcasts.apple.com/us/podcast/the-find-my-people-expert-panel-real-strategies-for/id1618590178?i=1000704117939 Spotify: https://open.spotify.com/episode/2sIqL2W8LXbvSJIZobwRci

Here's the raw audio from the Expert Panel at Cobra Con. Enjoy it! Ad free!!!!

In the latest episode of On The Line, we take a look (through our fingers, which are covering our eyes) at what's happening with the markets, and whole economies, around the world. Guess we'll be delaying retirement a few extra years, eh? This episode of On The Line is brought to you by Westinghouse. Canada's energy future is being shaped by the choices we make today. Westinghouse is 100% Canadian-owned and brings the world's most advanced, operational Gen III+ reactor — the AP1000® — proven, safe, efficient, and ready now. It can be brought online within a decade, delivering clean, reliable power when we need it most. Canada needs energy. Westinghouse is ready. Learn more at westinghousenuclear.com/canada.To unpack all that is happening, Jen Gerson speaks with Professor Barry Eichengreen. The professor is an American economist and economic historian who is the George C. Pardee and Helen N. Pardee Professor of Economics and Political Science at the University of California, Berkeley. And he is worried that this is the big one, an economic crisis to rival the Great Depression. He highlights the volatility in the markets, the weakening of the U.S. dollar, and the potential for long-term damage to international economic relations. The discussion also touches on the role of cryptocurrencies and the challenges faced by Canada in navigating these turbulent economic waters.This episode is also brought to by the Métis Nation of Ontario. It's Sault Ste. Marie, 2025. In a quiet room filled with maps, parish records, and the voices of history, a story long denied is finally told. For too long, Métis communities in Ontario had been questioned, overlooked, and denied. But after reviewing more than 50,000 pages of evidence, visiting the seven historic Métis communities in Ontario, and hearing from 160 Métis Nation elders, youth, scholars, and leaders — the truth is clear. The Métis National Council's Expert Panel report is the most comprehensive, transparent, and objective study ever conducted on Métis Nation communities in Ontario. The report rejected politically motivated misinformation. And it confirmed that the seven historic Métis communities in northern Ontario are — and have always been — part of the larger Métis Nation and meet the National Definition of Métis. For the Métis Nation of Ontario and their citizens, this report was a vindication. For more, go to OntarioMetisFacts.com.After that, Jen is joined by Mike Colledge from Ipsos, to provide an update on what issues are driving the electorate. Mike looks inside Ipsos's vast stores of data and shares with Jen what one of the next major issues in Canada could be: social cohesion.As always, like and subscribe at our main page, ReadTheLine.ca. You can also follow us on your favourite podcast app so you never miss an episode. Share it far and wide. Spread the word of The Line.

Today, we're heading to one of the world's most magical cities—Venice. Imagine wandering through winding canals, admiring centuries-old architecture, and indulging in traditional ciccheti and a select spritz. Whether you're here for the art, the food, or the timeless beauty, Venice has something special waiting for you. I'm joined by two incredible locals, Giovanna Santini and Nicole Zennaro, who share their insider tips on the best experiences, hidden gems, and the fascinating history that makes Venice so unique. From the canals to the cuisine, they'll have you falling in love with Venice all over again. I hope you enjoy this enchanting episode of Luxury Travel Insider. Learn more at www.luxtravelinsider.com   Connect with me on Social: Instagram LinkedIn  

Can Neurodiverse Relationships Work?

The first Alloutcoach episode of 2025 is a powerful and honest conversation from an unforgettable Expert Panel at the 2024 Medical Affairs Innovation Olympics about a much needed modern view of leadership in Medical Affairs, pharma, healthcare and beyond. The thought-provoking discussion will certainly challenge you and offer practical solutions. It features some of the most dynamic, accomplished leaders who provide intriguing, candid, and diverse perspectives across pharma and biotech, Medical Affairs, ESG, finance, technology, and life sciences backgrounds. Speakers: Melissa Norcross, AVP, Corporate Strategy and ESG, Hyland SoftwareChristopher Piedmonte, Managing Director, NeoTerra Capital, Tech Executive, Angel Investor Natasha Hansjee, Integrated Medical Enabling Catalyst, RocheTopics1. Leadership & Talent: What are the current gaps in innovative Medical Affairs leadership approaches from a talent management perspective – how do we maximize the power of medical decisions from a skillset and mindset perspective (AI savviness, critical thinking, innovative, digital HCP engagement)? 2. Measuring and Improving Impact on Patients: How can Medical Affairs continue to reinvent itself with emerging challenges, technology, or competitive sources of information that drive clinical decisions to instead utilize them appropriately yet demonstrate its independent value and impact in the future? 3. Decision-Driven Analytics – what case studies or best practices can we learn from in decision-driven analytics and excellence in internal decision-making and strategy across the different life cycles of products, devices, etc.4. How do we stimulate problem solving and adaptive performance, not only tactical performance to drive innovation in Medical Affairs? 0:11 Episode Highlights 8:20 Introduction of Panel 9:50 Moderator's Introduction - What Gaps are there in Medical Leadership? What does it mean to lead well? Provide not only skillsets but toolsets. Celebrate and stimulate failure.Emphasize customer experience15:46 Gaps in Clarity of vision, Access to Resources18:35 Setting the right foundation of trust and mindset as LeadersLeader's job is to help team members to avoid trouble, resolve problems and not assign blame.21:59 Empowerment comes through accountability, which is missingPerformance Feedback is critical23:57 Unlocking Innovation and Critical ThinkingPsychological safety is effective only when combined with AccountabilityTeaching others how to think in order to maximize performance25:20Leaders Drive Business PerformanceTrust and accountability fall along a spectrum, and are not opposites27:26 How do the greatest leaders drive more effective innovation? 31:44 Innovation through accidental discovery accelerated by Generative AIIn many ways AI stands for artificial intern vs artificial intelligenceHow critical collaboration is as well as competition33:45 At the edge of performance, athletes learn from other competitors who have superior skills.34:45 Case Studies of Utilizing Analytics to Drive Better Decisions36:45 Get diverse perspectives, from relevant and large groupsBeware of making assumptions based on data39:31 Take data you have available, match the quality of the data to make best decision. It is never perfect. Do more with less resources - innovation.43:14 Last Call to Action to Lead differently tomorrow in Medical AffairsClarity - Objectives, Timelines, Resources, Performance metricsVoice of Customer + Voice of Employee46:53 Find Someone to Compensate for your Blind Spots

With the support of Astemo, Global Auto Mobility met with student groups, associations, and teams – plus an expert panel of University of Michigan Dearborn professors – to discuss how industry, higher education, and students can collaborate to prepare for the future of engineering. We heard from Assistant Dean John Cristiano, as well as Professors Areen Alsaid, Alireza Mohammadi, and Samir Rawashdeh.

Welcome back to the Perfect Pour and the beginning of the 600s! This week we settle in and talk about beer stuff like: The Top Ten Beer Cities in the U.S. is... The Schlitz Is it even cheaper to home brew? AIM beer names. Beer at the Melvins. Taco Bell And more more more! Download: PerfectPour601.mp3 Thank you for listening! HOSTED BY: Nick, Rad Stacey, Mikey MUSIC BY: Sunburns and Paul From Fairfax. BEER AND SHOW RELATED LINKS: SUPPORT THE SHOW AND BECOME A GOLDEN GOD! Subscribe to the show in Apple Podcast. You can also find us on Spotify and most podcast players. Perfect Pour's YouTube Channel. VOICEMAIL/TEXT LINE: 559-492-0542 Drop Us a Line: Email Perfect Pour. Join our free Lager Line Discord channel! Send Postcards or Samples to us: The Perfect Pour – co Mike Seay 2037 W. Bullard Ave #153 Fresno, CA 93711 Mikey's newsletter: Drinking & Thinking. Browse Mikey's Dorky Amazon Storefront.

Today… we're going skiing! And we're doing it in style in France, Switzerland, Italy, and other European destinations. I wanted to pull together this episode not only because skiing in Europe is an amazing cultural experience, but also because it's looking pretty darn good from a value perspective right now. The Euro and Dollar are currently on par and lift tickets and lessons are massively cheaper in Europe than in the US.  Our guests today are the brother and sister team, Rick Reichsfeld and Richelle Blanken. The duo grew up skiing competitively, both raced in college, and then Richelle even raced in the Olympics. When Richelle left the national team - brother and sister teamed up to find a way to make a living from helping others experience the joy of skiing and the duo are our partners in planning amazing ski trips around the world for Bell & Bly Travel clients.   We discuss everything from Michelin starred mountain food, to unique lifts across Europe, to the most luxurious resorts, spas, and even non-skiing winter activities.  Sit back with a cup of hot chocolate or a glass of champagne, and enjoy this episode of Luxury Travel Insider.   Learn more at www.luxtravelinsider.com   Connect with me on Social: Instagram LinkedIn

Today… we're going skiing! And we're doing it in style in France, Switzerland, Italy, and other European destinations. I wanted to pull together this episode not only because skiing in Europe is an amazing cultural experience, but also because it's looking pretty darn good from a value perspective right now. The Euro and Dollar are currently on par and lift tickets and lessons are massively cheaper in Europe than in the US.  Our guests today are the brother and sister team, Rick Reichsfeld and Richelle Blanken. The duo grew up skiing competitively, both raced in college, and then Richelle even raced in the Olympics. When Richelle left the national team - brother and sister teamed up to find a way to make a living from helping others experience the joy of skiing and the duo are our partners in planning amazing ski trips around the world for Bell & Bly Travel clients.   We discuss everything from Michelin starred mountain food, to unique lifts across Europe, to the most luxurious resorts, spas, and even non-skiing winter activities.  Sit back with a cup of hot chocolate or a glass of champagne, and enjoy this episode of Luxury Travel Insider.   Learn more at www.luxtravelinsider.com   Connect with me on Social: Instagram LinkedIn  

In this heartfelt expert panel episode of the Do The Thing Podcast with hosts Laura Carney and Stacey Lauren. Laura created this Do The Thing Challenge for Modern Prairie. They gathered an amazing lineup of guests to dive deep into the ways we can Follow Our Hearts and transform our lives. Meet Anne Marie Wells, Shaun Zetlin, Jeff Truesdell, and Mary Latham as they share their unique journeys, battles, and triumphs—all fueled by the courage to listen to their inner calling.Hear inspiring stories, like Laura's journey with her dad's bucket list, Mary's cross-country kindness project, Anne Marie's Icelandic adventure seeking stories of joy, Shaun's emotional fitness mission, Jeff's love-driven visits to places named "Nelson," and Stacey's life-changing lessons from asking courageous questions.➡️ Watch now to learn practical tips from this motivated panel, including how to connect meaningfully with others, overcome fear, and take small but powerful steps to follow your heart—even when it feels scary.➡️ The panel also dives into how to build courage, seek transformation, and embrace life beyond your comfort zone.

Dr. Valentin Fuster discusses the February 2025 issue of JACC, which focuses on advancements in heart failure research. The discussion covers five key sections: heart failure with preserved ejection fraction, hypertrophic cardiomyopathy, cardiac amyloidosis, standardization of kidney function, and ICD therapy for primary prevention in heart failure patients. Experts explore emerging therapies, diagnostic thresholds, and the potential impact of blood pressure and genetics on patient outcomes, underscoring the need for comprehensive approaches in managing these complex conditions.

Send us a textIn this episode we talk with researcher Dr. Enette Larson-Meyer about:Thyroid Function and its importance to athletesNutrients needed for normal thyroid function and what can cause thyroid disruptionDr. Larson-Meyer, PhD, RD, CSSD, FACSM is a professor at Virginia Tech, where she directs the Nutrition and Exercise Metabolism Laboratory and the Master of Science in Nutrition and Dietetics program. She is trained in nutrition/dietetics and exercise science and her interests include energy and micronutrient metabolism, plant-based nutrition, and endocrine (non-diabetes) and metabolic disorders. Her research focuses on how nutrition influences the health and performance of active people at all stages of life and performance levels. Recent research includes healthy weight gain in athletes and the importance of micronutrient status—particularly iodine and vitamin D— in sports/exercise performance, disease prevention and general wellness. Enette has authored over 100 scientific articles and book chapters, is the author of “Plant-Based Sports Nutrition. Expert Fueling Strategies for Training, Recovery, and Performance” (Human Kinetics, 2020), and is an Associate Editor for Medicine & Science in Sports & Exercise and the Science and Medicine of Football. She served on the 2011 IOC Sports Nutrition Consensus Panel and the 2017 Expert Panel for Dietary Supplements and the High Performance Athlete, and is currently a member of the International Testing Agency Health & Clinical Expert Advisory Group. Enette also interned at the U.S. Olympic Training Center in Colorado Springs and served as the sports dietitian for the University of Alabama at Birmingham. Her personal interests include road cycling, flat water kayaking, Irish step dancing, resistance training, gardening, yoga, cooking and wine tasting. She is the mother of 3 athletic children, who consistently put her sports nutrition knowledge to the test.Please note that this podcast is created strictly for educational purposes and should never be used for medical diagnosis and treatment.Connect w/ Dr. Enette Larson-Meyer: X: @enettemeyerrdWeb / Google ScholarMentioned:Study: Thyroid Function and Nutrient Status in AthletesDr. Larson-Meyer on NR Episode #118MORE NR New customers save 10% off all products on our website with the code NEWPOD10 If you would like to work with our practitioners, click here: https://nutritional-revolution.com/work-with-us/ Save 20% on all supplements at our trusted online source: https://us.fullscript.com/welcome/kchannell Join Nutritional Revolution's The Feed Club to get $20 off right away with an additional $20 Feed credit drop every 90 days.: https://thefeed.com/teams/nutritional-revolution If you're interested in sponsoring Nutritional Revolution Podcast, shoot us an email at nutritionalrev@gmail.com.

In this panel discussion from my Jamaica Investment Conference, THROP-X, we explore the viability of Airbnb in Jamaica. This expert panel, including real estate professionals Maura Watson, Noel Phillips, and St. Aubyn Clark, delves into the current state of the Airbnb market, the increasing pressures from various fronts, and whether investing in Airbnb properties is still profitable.Discover insights on:- The average mortgage process in Jamaica- Essential steps for buying property- The role of surveys and valuations- The potential challenges faced by Airbnb hosts- How to navigate regulations and community rules- Whether you are an investor, property owner, or simply interested in the Jamaican real estate market, this discussion offers valuable perspectives and practical advice.Don't forget to like, comment, and subscribe for more expert insights on real estate investment in Jamaica!Topics Covered:- Average mortgage process in Jamaica- Importance of TRN and a good lawyer- Valuations and survey reports- Viability and challenges of Airbnb in Jamaica- The impact of government and social pressures on Airbnb- Join us to get the latest expert opinions on whether Airbnb is still a viable investment in Jamaica.#JamaicaRealEstate #Airbnb #THROPX #RealEstateInvestment #Jamaica #AirbnbJamaica #PropertyInvestmentTopics Covered:The current state of the Airbnb market in JamaicaChallenges facing Airbnb hosts and investorsThe process of buying property for AirbnbRisk vs. reward of investing in AirbnbFuture prospects for Airbnb in JamaicaDon't forget to like, comment, and subscribe for more insights on real estate investment in Jamaica!Chapter Markers:0:00 - Introduction1:16 - Panel Introduction and First Speaker2:09 - Cash Buyers vs. Mortgage Buyers3:00 - Challenges with Mortgage Timelines4:30 - Considerations for Residential Property Purchases5:48 - Role of Lawyers in Real Estate Transactions6:40 - Importance of Survey Reports8:36 - Site Visits and Property Inspections11:10 - Dealing with Property Boundary Issues14:00 - Importance of Home Inspections16:00 - Impact of Property Age on Valuations18:31 - Strata Restrictions on Airbnb20:21 - Government Regulations and Taxes on Airbnb22:21 - Ensuring Compliance with HOA and Strata Rules24:26 - Airbnb as a Business Opportunity26:01 - Balancing Hotel and Airbnb Markets30:07 - Future Regulations for Airbnb32:00 - Multi-Listing Services in Jamaica35:28 - Q&A: Property Valuation Process39:59 - Q&A: Government Plans for Airbnb Taxation42:02 - Q&A: Suggested Regulations for Airbnb47:59 - Q&A: Building Materials Used in Jamaica48:52 - Q&A: Regulation Impact on Airbnb Experience51:16 - Final Thoughts on Airbnb ViabilitySpeaker Contact InfoHost Amashika LorneIG: https://www.instagram.com/amashikalorne/?hl=enNoel Phillips ‭- 1 (876) 550-1600‬IG: https://www.instagram.com/iamnoeltherealtor/?hl=enMaura Watson ‭- 1(876) 413-2510‬IG: https://www.instagram.com/maurawat64/?hl=enSt. Aubyn Clarke - 1 (876) 550-1215‬IG: https://www.instagram.com/islandstyle.realestate/?hl=enMy Contacthttps://thropmedia.com/throp-xFacebook: https://www.facebook.com/throplife

Today, we're headed to the vibrant and historic city of Cartagena, Colombia. Imagine strolling through cobblestone streets lined with pastel buildings, enjoying the rhythm of cumbia music in the distance, or setting sail on turquoise waters to visit nearby islands. Joining me today are three incredible guests who know this city inside and out: my partner in the region, Cristina Consuegra and two of her expert guides, Maria Angelina and Fernando. Together, we dive into everything from Cartagena's must try food, to the influence of pirates on the region, to its booming art and fashion scene. Maria Angelina brings her perspective as an art curator and cultural heritage expert, while Fernando shares his deep knowledge as a historian specializing in the Colombian Caribbean Coast. Whether you're dreaming of a family getaway, a romantic escape, or an adventure filled with history and culture, this episode has something for you. Learn more at www.luxtravelinsider.com   Connect with me on Social: Instagram LinkedIn  

In today's special FDE+ Virtual Event episode, Kortney Harmon brings together four industry experts—Danny Cahill, JT Westendorf, Michele Massaro, and Chris Allaire—for a powerful panel discussion that covers essential topics for navigating the evolving landscape of recruiting and staffing.From leveraging new technologies and refining business strategies to understanding the pressing issue of talent shortages, this episode is packed with actionable takeaways and real-world advice to help you thrive in the coming year.Tune in as we explore how to blend tried-and-true techniques with innovative approaches to elevate your recruiting game. Whether you missed the live event or want to revisit the session's highlights, this episode has it all. Stay with us, and let's propel your success together!________________Follow Danny on LinkedIn: LinkedIn | Danny CahillFollow JT on LinkedIn: LinkedIn | JT WestendorfFollow Michele on LinkedIn: LinkedIn | Michele MassaroFollow Chris on LinkedIn: LinkedIn | Chris AllaireWant to learn more about Crelate? Book a demo hereFollow Crelate on LinkedIn: https://www.linkedin.com/company/crelate/Subscribe to our newsletter: https://www.crelate.com/blog/full-desk-experience

Send us a textJoin us for an exclusive deep dive into the world of multi-family offices, wealth advisors, and billion-dollar investment strategies. This panel brings together top financial experts managing billions in assets, sharing insights on alternative investments, private equity, real estate syndications, hedge funds, and the future of wealth management.

Today on the Clean Power Hour, host Tim Montague explores two critical aspects of modern solar development: effective industry partnerships and IRA compliance. Four industry veterans share insights on how collaboration and compliance can coexist with aggressive timelines:Successful Partnership Dynamics:OMCO and Sunstall have collaborated on over 100 projects together, including nearly 100 projects for Coldwell Solar in CaliforniaKey success factors include:Rapid response time for field issues due to domestic manufacturingProduct evolution based on installer feedback, particularly bearing designs that accommodate field conditionsConsistent communication and clear expectations between all partiesProper sequencing of material deliveries (piles first, followed by racking)Real World Example - Wilcox Project:4MW ‘multi-site' project (powering a greenhouse complex) completed in 8 weeks from initial contact to completion.Success attributed to:OMCO's ability to manufacture and ship from the Phoenix facility Sunstall's rapid team mobilizationObodo Energy's decisive project management and clear communicationIRA Compliance & Domestic Content:OMCO Solar (Eric Goodwin) detailed their domestic manufacturing capabilities, currently at 88% domestic content for trackers with 100% expected by Q2 2025Their fixed-tilt products already meet 100% iron and steel requirementsOMCO benefits from the 45X manufacturing tax credit, helping level pricing with international competitorsThe discussion demonstrated how strong partnerships between manufacturers, installers, and EPCs can maintain efficient project timelines while meeting IRA requirements, with communication and trust serving as foundational elements for success.Social Media HandlesEric GoodwinMatt KesslerOmco SolarHelge BiernathSunstallJohn MitmanAbodo Energy Support the showConnect with Tim Clean Power Hour Clean Power Hour on YouTubeTim on TwitterTim on LinkedIn Email tim@cleanpowerhour.com Review Clean Power Hour on Apple PodcastsThe Clean Power Hour is produced by the Clean Power Consulting Group and created by Tim Montague. Contact us by email: CleanPowerHour@gmail.com Corporate sponsors who share our mission to speed the energy transition are invited to check out https://www.cleanpowerhour.com/support/The Clean Power Hour is brought to you by CPS America, maker of North America's number one 3-phase string inverter, with over 6GW shipped in the US. With a focus on commercial and utility-scale solar and energy storage, the company partners with customers to provide unparalleled performance and service. The CPS America product lineup includes 3-phase string inverters from 25kW to 275kW, exceptional data communication and controls, and energy storage solutions designed for seamless integration with CPS America systems. Learn more at www.chintpowersystems.com

Anne Blaes, MD, and Nicholas Wilcox, MD, MHS discuss JACC: CardioOncology Expert Panel Recommendations for cardiovascular care and surveillance after cancer therapy, including available evidence, practical recommendations, and key evidence gaps.

Get my new book: https://bronsonequity.com/fireyourself Download my new special report - How to Use Inflation to Your Advantage - www.bronsonequity.com/inflation Welcome to our latest episode! Today, we are thrilled to feature an extraordinary panel of real estate experts: Kathy Fettke, Veena Jetti, Kaaren Hall, and Ashley Wilson. These trailblazing women share their diverse insights on navigating today's real estate market, leveraging innovative strategies, and embracing opportunities during challenging times. Kathy Fettke is a seasoned investor and media personality, co-founder of RealWealth, and host of "The Real Wealth Show" and "Real Estate News for Investors." Kathy offers a unique perspective on real estate trends and economics, empowering investors to achieve financial freedom. Veena Jetti, founder of Vive Funds, is a multifamily expert managing a $1 billion portfolio. Known for her innovative approaches to real estate and deep expertise in finance, Veena is passionate about scaling and creating value in her deals. Kaaren Hall, CEO of uDirect IRA Services, is a leading authority on self-directed IRAs and retirement investing. She helps investors unlock alternative asset opportunities, from real estate to precious metals and more. Ashley Wilson, co-founder of Bar Down Investments and author of The Only Woman in the Room, is a multifamily operations expert who has managed over $13 million in construction projects and 1,500 units. Ashley's meticulous approach to operations drives unparalleled results. In this episode, the panel discusses the current state of real estate investing, including strategies for navigating rising interest rates, value-add projects, and creative financing. They explore how operations excellence can mitigate risks and provide a competitive edge, while touching on innovative approaches like 3D-printed housing and container homes. The conversation also delves into the critical role of women in real estate, challenges faced in the industry, and opportunities to create inclusive spaces for future leaders. Tune in now to learn from these powerhouse women about how to thrive in today's real estate landscape and beyond! TIMESTAMPS 00:05 – Guest intro: Kathy Fettke, Veena Jetti, Kaaren Hall, and Ashley Wilson 01:10 – Challenges and opportunities in the current real estate market 04:45 – Rising interest rates and their impact on investments 09:20 – Strategies for creative financing and value-add projects 14:15 – Innovative solutions in construction, including 3D printing and container homes 20:30 – Self-directed IRAs for real estate investing 32:45 – Unique opportunities in today's real estate landscape 40:20 – Diversity and inclusion in real estate leadership 49:15 – Key takeaways and actionable insights from the panel 56:00 – Closing remarks Connect with the Guests: Kathy Fettke Website: https://realwealth.com/ LinkedIn: https://www.linkedin.com/in/kathyfettke/ Instagram: https://www.instagram.com/kathyfettke/?hl=en Linktree: https://link.me/kathyfettke Veena Jetti Website: https://vivefunds.com/ LinkedIn: https://www.linkedin.com/in/veenajetti/ Instagram: https://www.instagram.com/veenajetti/?hl=en Kaaren Hall Website: https://udirectira.com/ LinkedIn: https://www.linkedin.com/in/kaarenhall/ Instagram: https://www.instagram.com/kaarenhall/ Ashley Wilson Website: https://www.bardowninvestments.com/ LinkedIn: https://www.linkedin.com/in/badashinvestor/ Instagram: https://www.instagram.com/badashinvestor/?hl=en Linktree: https://linktr.ee/BadAshInvestor #RealEstateInvesting #WomenInRealEstate #RealEstateMasters #RealEstateInnovation #InvestmentStrategies

Today we're setting off on a journey through the misty glens and rugged coastlines of Scotland—a land where history and legend intertwine.  Joining me today are Christopher Sleigh and Euan House, two incredible storytellers and partners of ours in the region. Together, we unravel the history of the clan structure, explore the difference between a tartan and a kilt, take a walk through Scotland's local food markets, and of course talk a little bit about Outlander too.   Whether you're drawn to the charm of the Highlands or the cultural pulse of its cities, this episode will inspire your next Scottish adventure!  Learn more at www.luxtravelinsider.com   Connect with me on Social: Instagram LinkedIn  

Join Army Veteran & Federal Air Marshall Matt Cubbler, WV House & Jan. 6 Political prisoner Derrick Evans, Benghazi & Extortion 17 Whistleblower Nick Noe, and your Host Jeremy Slayden for this expert panel on geopolitics. follow my exclusive work at jslayusa.com

Welcome to the 2024 besties episode of Luxury Travel Insider. I've invited two of my best friends, Kristen Sandvig and Hao Tang, to join me to dish on all things travel.  All three of us are professional travelers, spending up to a third of our years out of the country. It's our job to be discerning… and maybe a little snobby!  So, in this unfiltered conversation you'll hear our opinions on everything from hotels, to interesting experiences, airports, pet peeves and more. There'll be a lot of laughing and some great insights and travel tips.  Before we dive in, I want to thank you for being a part of our community, for listening, for sending me your feedback, for working with Bell & Bly Travel for your luxury travel needs. It's truly an honor to inspire you to travel the world and I'm looking forward to many more chats in 2025.  Learn more at www.luxtravelinsider.com   Connect with me on Social: Instagram LinkedIn  

Cybersecurity Year in Review: Future Challenges and Industry Insights Join host Jim Love and a panel of cybersecurity experts—Terry Cutler from Cyology Labs, David Shipley from Beauceron Security, and Laura Payne of White Tuque—as they review the key cybersecurity events of the past year. Topics discussed include the increasing cyber threats to universities, healthcare systems, and critical infrastructure; the importance of proper cybersecurity measures and employee training; the complexities of adopting quantum-safe encryption protocols; and the impact of AI and shadow IT on cybersecurity. The panel concludes with actionable advice for improving organizational cybersecurity posture in the coming year. 00:00

This panel discussion examines critical considerations as artificial intelligence and automation technologies become increasingly integrated into behavior analytic practice. Expert panelists explore the implications of AI for clinical decision-making, documentation, training, and equitable service delivery while emphasizing the importance of maintaining human clinical judgment and ethical practice. The discussion highlights both opportunities and risks, providing behavior analysts with key considerations for evaluating and implementing AI tools in their practice while maintaining professional and ethical standards. To earn CEUs for listening, click here, log in or sign up, pay the CEU fee, + take the attendance verification to generate your certificate! Don't forget to subscribe and follow and leave us a rating and review. Show Notes References:   Council of Autism Service Providers. (2024, October 24). CASP announces workgroup to develop artificial intelligence (AI) guidelines [Press release].  Council of Autism Service Providers. (2023). Applied behavior analysis practice guidelines for the treatment of autism spectrum disorder: Guidance for healthcare funders, regulatory bodies, service providers, and consumers (Version 3.0).  Council of Autism Service Providers. (2022). Practice parameters for telehealth-based applied behavior analysis: Special considerations and recommendations for practitioners, funders, and regulators.  Resources:   Behavioral Health Center of Excellence (BHCOE) - www.bhcoe.org  CentralReach - www.centralreach.com  CARI by CentralReach - https://centralreach.com/blog/meet-cari-the-generative-ai-solution-from-the-leader-in-autism-and-idd-care-software/  Council of Autism Service Providers (CASP) - www.casproviders.org  TransformVXR - www.transformvxr.com 

Dr. Van Morris presents the new evidence-based guideline on systemic therapy for localized anal squamous cell carcinoma. Dr. Morris discusses the key recommendations from the Expert Panel, including recommended radiosensitizing chemotherapy agents, dosing and schedule recommendations, the role of induction chemotherapy and ongoing adjuvant chemotherapy, and considerations for special populations. He emphasizes the importance of this first guideline from ASCO on anal squamous cell carcinoma for both clinicians and patients with stage I-III anal cancer, and ongoing research the panel is looking to for the future. Read the full guideline, “Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline” at www.asco.org/gastrointestinal-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/gastrointestinal-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02120 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts, delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Van Morris from MD Anderson Cancer Center, co-chair on “Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline.” Thank you for being here today, Dr. Morris. Dr. Van Morris: Thank you for having me. On behalf of our committee who put together the guidelines, I'm really excited to be here and talk with you today. Brittany Harvey: Great. Then, before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Morris, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to jump into the content of this guideline, Dr. Morris, can you provide an overview of both the purpose and the scope of this guideline on stage I to III anal squamous cell carcinoma? Dr. Van Morris: So anal cancer is considered a rare malignancy for patients in the United States and across the world as well. Even though it's not something we see as commonly, for example, as the adjacent colorectal cancer, this still is a cancer that is rising in incidence every year in the United States. And really, despite the presence of the preventative HPV vaccines, which we hope will ultimately prevent and eradicate this cancer, we still expect the incidence to continue to rise in the coming decades before we really start seeing numbers begin to decrease as a result of the vaccine. So this is an alarming trend for which oncologists will continue to see likely more and more cases and new diagnoses every year. So we wanted to review the most recent literature and provide oncologists up to date recommendations for how they can best take care of patients with a new diagnosis of localized anal cancer. Brittany Harvey: Absolutely. I appreciate that background and context to set the stage for this guideline. So then next I'd like to review the key recommendations of this guideline. So starting from the first clinical question, what are the recommended radiosensitizing, doublet or single chemotherapy agents for patients with stage I to III anal cancer? Dr. Van Morris: It's true that really the standard treatment for patients with localized anal cancer has not changed over the last literally half century. When the Nigro regimen was first reported back in 1974, 50 years ago, the standard of care for patients with a new diagnosis of localized anal cancer centers around concurrent chemotherapy and radiotherapy. And we looked at the various randomized control trials and the highest level of evidence which has been reported over the past decades, and really for most patients, the standard of care continues to remain doublet cytotoxic chemotherapy in combination with radiation. We reported that the most commonly, and I think most accepted, regimen here is a combination regimen of 5-FU, intravenous 5-fluorouracil with mitomycin C. And this most commonly is given on a week 1 to 5 regimen. The 5-FU, we recommended a dose of 1000 milligrams per meter squared per day on days 1 to 4 and then on days 29 to 32 of the radiation treatment. And then the mitomycin C, looking at various trials, has been given at a dose of 10 milligrams per meter squared on day 1 and day 29, or alternatively a single dose of mitomycin C at 12 milligrams per meter squared on day 1. I think that the thing that's important for clinicians and patients alike to remember is that this chemotherapy can be very toxic in patients who are undergoing a curative-intent therapy for this diagnosis of localized anal cancer. I think it's just important for oncologists to be watching closely the blood counts for the patients to make sure that the myelosuppression doesn't get too bad. And then in select cases, if that is the case, when the oncologist opts to go for the day 1 and day 29 dosing, it may be prudent, if the myelosuppression is too excessive, to consider withholding that day 29 dose. Brittany Harvey: Great. Thank you for providing those recommendations along with some of those dosing and the schedule recommendations from the expert panel. So are there any other alternate dose or schedule recommendations from the expert panel? Dr. Van Morris: Yeah, but I think that we saw with the ACT II data that was a randomized trial that was done out of the UK that compared 5-FU mitomycin with 5-FU cisplatin as two different doublet cytotoxic regimens, that overall outcomes were very similar between the two regimens in terms of curative outcomes for patients treated whether 5-FU mitomycin or 5-FU cisplatin. So certainly there is evidence supporting the use of cisplatin as a second cytotoxic agent with 5-fluorouracil. In the ACT II study that was given at a dose of 60 milligrams per meter squared on days 1 and 29 along with the 5-FU at the regimen I talked about previously. There is other lower level of evidence data suggesting that even the 5-FU and cisplatin can be given on a weekly schedule and that that can be safe. Actually, at my institution at MD Anderson, that is our standard practice pattern as well. There's also the option when we're thinking about giving pelvic radiation for patients with lower GI cancers, many oncologists in the treatment of localized rectal adenocarcinoma are accustomed to using capecitabine as a chemosensitizer in patients with localized rectal cancer. If I'm giving chemoradiation for a patient with localized anal cancer, can I substitute the intravenous 5-FU with oral capecitabine? And although the evidence is not as strong in terms of available data with regards to randomized controlled trials, there certainly is data that suggests that capecitabine may be an acceptable alternative in lieu of intravenous 5-fluorouracil that would be given at a dose of 825 milligrams per meter squared on days of radiation. But certainly, I think that that's a feasible approach as well and maybe even associated with less hematologic toxicity than intravenous 5-FU would be. Brittany Harvey: Great. It's important to understand all the options that are out there for patients with early-stage anal squamous cell carcinoma. So in addition to those chemoradiation recommendations, what is recommended from the expert panel regarding induction chemotherapy or ongoing adjuvant chemotherapy for this patient population? Dr. Van Morris: When we think about treating patients with lower GI cancers with curative intent therapies, when we think about the more common rectal adenocarcinoma, oncologists may be used to giving chemoradiation followed by subsequent cytotoxic chemotherapy. But actually when you look at the data for anal cancer, really there's not any data that strongly supports the use of either induction chemotherapy prior to chemoradiation or adjuvant post-chemoradiation chemotherapy. The RTOG 98-11 study was a trial which evaluated the role of induction 5-fluorouracil prior to chemoradiation and did not show any survival benefit or improved outcomes with the use of induction chemotherapy in a randomized control trial setting. The ACT II trial, which I referenced earlier, was a 2 x 2 design where patients were either randomized to concurrent chemoradiation with 5-FU mitomycin C or concurrent chemoradiation with 5-FU cisplatin. But then there was a second randomization after chemoradiation where half of the study participants received adjuvant cisplatin 5-fluorouracil after completion of their chemo radiation, or the other half were randomized to the standard of care, which of course would be observation. And what that trial showed was that there was no added benefit with the addition of post-chemoradiation cytotoxic chemotherapy. So we look at these data and say that in general, for the general population of patients with localized stages I to III anal cancer, there really is no supporting data suggesting benefit of either induction chemotherapy or adjuvant chemotherapy. And to that end, really it's concurrent chemoradiation remains the standard of care at this time for patients with a new diagnosis of localized anal cancer. Brittany Harvey: Absolutely. It's just as important to know what is not recommended as it is to know what is recommended for these patients. And so I thank you for explaining the evidence behind that decision from the panel as well. So then, are there any other considerations for special populations that oncologists should consider? Dr. Van Morris: I think so. I think that anal cancer is a disease where we don't see that many patients being diagnosed earlier at a younger age, especially in relation to the alarming trend of early onset colorectal cancer that we're currently seeing right now. So there may be patients who come with a new diagnosis of localized anal cancer who are an octogenarian at an advanced age or may have other significant medical comorbidities. And if that is the case, we get called about this quite frequently from outside institutions. I have an 85 year old who is coming to my clinic with this diagnosis. I don't feel comfortable giving this patient doublet cytotoxics, what options do I have? Especially given other organ dysfunction that may precede this diagnosis. And I think that in that case, there are times when it's okay safely to drop the mitomycin C and opt for single agent 5-fluorouracil as a single cytotoxic agent. So I think that that would be something that we've certainly incorporated into our practice at our institution. There's also an association between various autoimmune disorders, patients on immunosuppression, even persons living with HIV being at higher risk for this virally associated cancer. So I think that, again, if the patient is coming with baseline immunosuppression for these reasons prior to treatment, certainly kind of being in tune to the potential for hematologic toxicity. And watching these patients very closely as they're getting chemoradiation remains really important. Brittany Harvey: Definitely. So, you've just discussed some of those comorbidities and patient characteristics that are important for clinicians to consider when deciding which regimens to offer. So in addition to those, in your view, what is the importance of this guideline and how will it impact clinical practice for clinicians who are reading this guideline. Dr. Van Morris: Chemoradiation remains a very effective option and most patients will be cured with this diagnosis and with this treatment. So it's important to make sure that these patients are able to safely get through their treatment, minimizing treatment delays due to toxicities which may come about because of the treatment, and really help to carry them over the finish line so that they have the best likelihood for achieving cure. So we really hope that these data will provide oncologists with a readily available summary of the existing data that they can refer to and continue to help as many patients as possible achieve and experience a cure. Brittany Harvey: Absolutely. So then to build on that, it's great to have this first guideline from ASCO on anal squamous cell carcinoma. But how will these new recommendations affect patients with stage I to III anal cancer? Dr. Van Morris: I certainly hope it will allow patients and oncologists to know what their options are. It certainly is not a one size fits all treatment approach with regards to the options which are available. Depending on the patient, depending on the various medical conditions that may accompany them, these treatments may need to be tailored to most safely get them through their treatment. Brittany Harvey: I appreciate you describing the importance of this guideline for both clinicians and patients. So what other outstanding questions and future research do you anticipate seeing in this field? Dr. Van Morris: It's a really good question and I think that there is a lot coming on the horizon. Even though the standard treatment has really not changed over the last half century, I think it still remains true that not all patients will achieve cure with a chemoradiation treatment. So a recent trial has completed enrollment in the United States, this is the EA2165 trial led by one of our committee members, Dr. Rajdev and Dr. Eng as well, that's looking at the use of nivolumab anti PD-1 immunotherapy after completion of concurrent chemo adiation. So in that trial, patients were randomized to concurrent chemoradiation followed by either observation or six months of adjuvant anti PD-1 therapy. We're really awaiting the results of that. Hopefully if we see an improvement with the addition of nivolumab following concurrent chemoradiation, our hope would be that more patients would be able to achieve a cure. So we're certainly looking forward to the outcomes of that EA2165 study. And then I think one question that we often get from our patients in the clinics is, “What is the role of circulating tumor DNA in the management of my disease?” And really, to date there have been some series which have shown that we can assess patients or circulating tumor DNA after completion of their concurrent chemo radiation that may need to start about three months after to give time for the radiation to wear off and most accurately prognosticate that. But I think that this will be a powerful tool moving forward, hopefully, not only in the surveillance to identify patients who may be at high risk for recurrence, but ultimately to translate that into next generation clinical trials which would treat patients at higher risk for recurrence by virtue of a detectable circulating tumor DNA result. In doing so, hopefully cure even more patients with this diagnosis. Brittany Harvey: Yes, we'll look forward to these developments and hope to add more options for potential treatment and surveillance for patients with anal cancer. So, I want to thank you so much for your work to develop these guidelines and share these recommendations with us and everything that the expert panel did to put this guideline together. Thank you for your time today, Dr. Morris. Dr. Van Morris: Thank you. And thank you to ASCO for helping to keep this information out there and ready for oncologists for this rare cancer. Brittany Harvey: Absolutely. And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.    

Podcast host Shawn McNiel, MD, is joined by Michael Incze, MD, MSEd to discuss his new article Expert Panel Consensus of the Effectiveness and Implementation of Models to Support Posthospitalization Care Transitions for People With Substance Use Disorders which aimed to establish a hierarchy of existing SUD care transition models in 2 categories-effectiveness and implementation-using an expert consensus approach. Dr. Michael Incze is a primary care physician in the Division of General Internal Medicine who is board certified in internal medicine and addiction medicine. His clinical interests include patient education, high value care, and caring for vulnerable populations including people experiencing homelessness and people with substance use disorders. He regularly volunteers at the Fourth Street Clinic, a federally qualified health center that specialized in providing care to people experiencing homelessness. He is a volunteer physician at the Rosebud Indian Health Service hospital in South Dakota. He also founded a clinic that focuses on providing primary care-based addiction treatment at Sugarhouse Health Center.

In this episode Allen hosts Pete DeMar, who has over 50 years of experience in the stationary battery industry, shared his background and expertise in battery failure analysis. Al Warner, with a history of involvement in batteries since his time on the farm, shared his experiences in the military and the UPS industry, highlighting his learning journey and continued interest in battery maintenance.Episode Highlights4:53 – I was, I guess, the whistleblower for VRLA batteries. I had, the main manufacturer at the time come to my location and had a battery assembled for them. I showed them every problem that they have with them. So IEEE came out with a document called IEEE 1188, and that became the standard for maintenance of VRLA batteries.11:56 – UPS batteries are the heart of the UPS system. If you don't have a battery, it's not uninterruptible so battery maintenance is critical.22:28 – Control algorithms that monitor the batteries kind of put the customer to sleep believing that the UPS is going to give them a warning before it fails, but that doesn't always happen.22:28 – A brownout is where the utility lowers the voltage so they can provide for a few more customers and then there's of course the famous blackout and rolling blackouts.29:24 – A totally separate problem that we have not actually discussed is, there are two things and one of those is, with large UPSs and DC battery systems, the arc flash calculations, they are way off.49:35 – They're relying on the electronics to Safely take care of their batteries. Same thing is true with UPSs. They rely on the electronics and no inspection It's out of mind, out of sight.

Send us a textWomen can expect to live five years longer than men. How are you going to make the best of it? Longevity. The concept itself has been around for a very long time - gaining traction as a "buzzword" in recent decades. It has now evolved into a lifestyle movement. Our guest on today's episode of the Ageless Glamour Girls Podcast is a longevity expert is all over that, and has been so for a long time. And Maddy Dychtwald has put all of her knowledge into a phenomenal new book - a national bestseller: "Ageless Aging: A Woman's Guide to Increasing Healthspan, Brainspan, and Lifespan."We are in the midst of a longevity revolution. And that's particularly true for women: *Women can expect to live five years longer than men *A 50-year old woman will live an average of 35 more years. *Women comprise 80% of centenarians, now the fastest growing segment of the world's population. But despite these incredibly hopeful statistics showing how women are living longer, women are not necessarily living well.BIO: Maddy Dychtwald Recognized by Forbes as one of the top fifty female futurists globally, for nearly 40 years, Maddy Dychtwald has been deeply involved in exploring all aspects of the age wave and how it's fundamentally transforming our lives and the world at-large. This has led her to become a national best-selling author, acclaimed public speaker, and thought leader on longevity and aging, health, wellness, and the new retirement. Maddy co-founded Age Wave, the world's leader in understanding and addressing the far-reaching impacts of longevity and our aging population. The Age Wave team has worked with more than half of the Fortune 500 in industries ranging from healthcare and medical technology to financial services and consumer products.With women at the forefront of the longevity revolution, Maddy has dug deep into their specific longevity-related wants, needs, challenges and opportunities. As a researcher and social scientist, she has led numerous acclaimed studies, including the landmark Women, Money and Power sponsored by Allianz and Women and Financial Wellness: Beyond the Bottom Line for Bank of America Merrill Lynch. In addition, she has been involved in more than 25 thought leadership research studies worldwide on longevity, aging, retirement, health and wellness, family and social connections, purpose, caregiving, finances, and leisure, which have cumulatively garnered more than twenty billion media impressions. As a blogger and member of The Wall Street Journal's Expert Panel, Maddy's posts on leadership, wealth management, and financial planning have topped the most-read lists. Her insights and research have been featured in prominent media outlets, including Bloomberg Businessweek, Forbes, Newsweek, Time, Fox Business News, CNBC, and NPR.https://maddydychtwald.com/  Instagram:@maddydychtwalSupport the showwww.linkedin.com/in/marqueetacurtishaynes www.agelessglamourgirls.com https://www.youtube.com/@agelessglamourgirls Instagram and Facebook: @agelessglamourgirlsFacebook: https://www.facebook.com/agelessglamourgirlsPrivate (AGG) FB Group: The Ageless Café: https://www.facebook.com/groups/theagelesscafeTikTok: @agelessglamourgirlsPodcast Producers: Purple Tulip Media, LLC and WEG Media Group, LLC

Dr. Greg Kalemkerian reviews the latest evidence-based rapid update from the Expert Panel on systemic therapy for small cell lung cancer. He discusses the updated recommendations for patients with limited-stage SCLC based on the ADRIATIC trial, and for patients with relapsed SCLC based on the DeLLphi-301 trial. Dr. Kalemkerian shares insights on what these changes mean for clinicians and patients, and highlights new trials in progress to provide more options for patients diagnosed with SCLC. Read the full rapid update, “Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update” at www.asco.org/thoracic-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02245   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Greg Kalemkerian from the University of Michigan, lead author on, “Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update”. Thank you for being here today, Dr. Kalemkerian. Dr. Greg Kalemkerian: Thank you. Thank you for the invitation. Brittany Harvey: Great. Then, before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Kalemkerian, who has joined us here today, are available online with the publication of the update in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content of this rapid update, Dr. Kalemkerian, what prompted this update to the Systemic Therapy for Small Cell Lung Cancer Guideline, which was previously published in 2023? Dr. Greg Kalemkerian: So even though the original guideline only came out a year ago, the past year we've seen two significant advances in small cell lung cancer with two reports, one in limited stage with the addition of immunotherapy, the other in the addition of a new immunotherapeutic agent in relapsed small cell lung cancer. Brittany Harvey: It's great to have this new data in the small cell lung cancer space. So based on these new changes, what are the updated recommendations from the expert panel? Dr. Greg Kalemkerian: So the first recommendations have to do with patients with limited-stage small cell lung cancer based on the ADRIATIC trial which added consolidation durvalumab for patients who had not had progression after standard chemotherapy and radiotherapy. And this study demonstrated a significant improvement in overall survival with about a 10% improvement in both 2- and 3-year overall survival, up to a 57% overall survival at 3 years for the patients receiving consolidation durvalumab. And based on those findings, we updated the recommendation for the standard treatment for limited-stage small cell lung cancer such that it included the use of consolidation immunotherapy with durvalumab for up to two years in patients who had had no disease progression, and completion of concurrent chemoradiotherapy for limited-stage small cell lung cancer. Of course, those patients would be those who do not have contraindications to the use of immunotherapy. As a corollary to that recommendation, for patients who have poorer performance status, so performance status of 3 or 4, who had had initial treatment perhaps with sequential chemotherapy and radiotherapy, if their performance status improves with their initial treatment, then it would also be reasonable to add consolidation immunotherapy for those patients as long as their performance status maintains improvement and they have no evidence of progression. The other update of the guidelines had to do with patients with relapsed small cell lung cancer and that was based on the DeLLphi-301 trial which was a phase II study looking at the use of tarlatamab, a bispecific T cell engager, binds to both DLL3 and CD3 in order to increase the immune killing of small cell lung cancer cells. So what this study did was it treated patients who had had at least two prior regimens. So this is third-line or beyond was what the population that this study looked at. And the majority of these patients had already had some immune checkpoint therapy. They all had good performance status and it did allow patients with brain metastases to be included in the study. When we look at the patients who received the approved 10 milligram dose of the drug, the response rate was about 40%. Responses were seen in both patients with sensitive and refractory based on the time since their prior treatment and the median duration of response was 10 months, which is much better than anything we've seen before with relapsed small cell lung cancer patients, remembering that all these patients were also third-line or beyond. So based on the results of the DeLLphi-301 trial, we updated two of the recommendations regarding relapsed small cell lung cancer. In the first one, we stated that in patients with relapsed small cell lung cancer with a chemotherapy free interval of less than 90 days, single agent systemic therapy would be considered standard of care, and that the preferred agents would include topotecan, lurbinectedin, or, now, tarlatamab. We did mention as a qualifying statement that single-agent chemotherapy is preferred over multi-agent chemotherapy. And the second recommendation was that, in patients with relapsed small cell lung cancer with a chemotherapy interval longer than 90 days, the rechallenge with a platinum-based regimen or single-agent chemotherapy was considered standard and the preferred agents for single agent therapy would be topotecan, lurbinectedin, or tarlatamab being added in the recent study. Tarlatamab was approved by the FDA for use in patients with relapsed small cell lung cancer with no stipulations with regard to the treatment. Brittany Harvey: Understood. I appreciate you describing those updated recommendations along with the supporting data for both limited stage small cell lung cancer and relapsed small cell lung cancer. So then, what should clinicians know as they implement these new and updated recommendations into practice? Dr. Greg Kalemkerian: So with regard to the ADRIATIC trial or the consolidation durvalumab being added for limite- stage small cell lung cancer patients, I think the important considerations are that this was done after patients had demonstrated no progression of disease after chemotherapy and radiotherapy, so the initial treatment does not change with platinum-etoposide plus definitive radiotherapy being recommended. The addition of durvalumab is going to be potentially useful in patients generally with good performance status, so performance statuses 0 to 1, and we still have to pay attention to the patients who may have contraindications to immunotherapy, things like interstitial lung disease, autoimmune problems that do occur in patients with small cell lung cancer where they develop paraneoplastic autoimmune syndromes such as Lambert-Eaton myasthenic syndrome. Those patients with those types of preexisting conditions would not be good candidates for immunotherapy use. So still having the tailored treatment to the individual patient is what's most important. The duration of the durvalumab was up to two years and not beyond that, so following those specific guidelines for the use of durvalumab in patients with limited-stage small cell lung cancer. With regard to tarlatamab, tarlatamab is an immunotherapy treatment. So we still do have the exclusions of people who have had prior severe immune-related adverse events, people who have pneumonitis, people who have interstitial lung disease, people with autoimmune neurologic problems we can see with small cell lung cancer, these patients should not be considered good candidates for the use of tarlatamab. The study did include patients who had had treated and asymptomatic brain metastases and there is some evidence that tarlatamab can have some control of brain metastases. So that's not necessarily an exclusion. Tarlatamab does have some other specific considerations to it in that 51% of patients had some evidence of cytokine release syndrome (CRS). Only 1% of those patients had grade 3 CRS. So even though they had frequent fevers and hypotension and hypoxia, it was generally not severe. But this concern for CRS and also for neurologic complications after treatment does require that patients be admitted to the hospital for a 24-hour observation period during the first and second doses. Subsequent to that, patients can be observed for some time after the infusion in the outpatient setting. But they also need to have very clear and strict guidance for when they go home about what things to look for. Looking for fevers, looking for shortness of breath, looking for any neurologic changes. It's a good idea for them to have a caregiver with them in order to observe them during that time. Most of these complications occur during the first or second cycles, but it is a drug that is going to require significant education not only of our staff, but also of the patients in order to ensure that the drug's used safely. Brittany Harvey: Absolutely. For these new options, it's important to tailor cancer treatment to the individual patient and the factors that you mentioned and be mindful of these potential toxicities. So, it's always great to learn of new options for patients. But in your view, how will this update impact patients with small cell lung cancer? Dr. Greg Kalemkerian: Well, clearly we need longer term follow up. So, with regard to the limited-stage small cell lung cancer situation, that's a curative situation. We have been curing patients with limited-stage disease with chemotherapy and radiotherapy for several decades now, but the cure rates were relatively low with about 25%, 30% of people becoming long term survivors. Now the hope is with the durvalumab being added on, that we can increase that number. Thus far, we have three-year survival data with a three-year survival of 57% overall survival and we're hoping that that is maintained over time and that we're not just delaying recurrences, but that we're actually preventing recurrences and helping people live longer, as has been seen with non-small cell lung cancer in stage III disease with the addition of durvalumab to chemoradiotherapy. So hopefully, we will be improving the cure rate of people with limited-stage small cell lung cancer. There are several other trials with immunotherapy in this space coming down the line and we're anxiously awaiting not only long term follow up from ADRIATIC, but also initial data from studies such as KEYLYNK and ACHILLES and NRG-LU005. So all of these studies in the next few years are hopefully going to guide treatment for limited-stage small cell lung cancer and hopefully improve the long term survival outcomes. With regard to tarlatamab, unclear at this point what the long term outcomes are going to be. Is a 40% response rate substantially better than what we've seen before? Well, lurbinectedin also had about a 40% response rate in patients who had sensitive disease, but the duration of response does look longer. And there are some patients now who have been on this study that are doing very well for quite long periods of time with the drug. So, the hope here also is that we will have some small subset of patients who continue to do better for long periods of time. Whether that'll translate into a cure or not, way too early to know, clearly hoping to add another brick in the wall so that we can keep the disease at bay, at least for a longer period of time for these patients. How we will integrate tarlatamab into the regimens is a bit unclear. Whether most of us will start using it as second-line therapy or whether we will use perhaps lurbinectedin or topotecan as second-line and tarlatamab as third-line, we're all going to have to work that out based on the potential toxicities, the logistical complications of using the drug at this point in time. But I do think that it's nice to have more options to add to our armamentarium to treat this very, very challenging and difficult disease. Brittany Harvey: Definitely. So, you've just discussed the need for both longer term follow up here along with some important ongoing trials in this space. So we'll look forward to future readouts of those trials to learn more about caring for patients in small cell lung cancer. So, I want to thank you so much for your work to rapidly update this guideline and thank you for your time today, Dr. Kalemkerian. Dr. Greg Kalemkerian: Okay. Again, thank you for the invitation, Brittany, and thanks to ASCO for developing the whole guideline structure to help all of us take better care of our patients. Brittany Harvey: Absolutely. And also thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full update, go to www.asco.org/thoracic-cancer-guidelines.  You can also find many of our guidelines and interactive resources in the free ASCO Guidelines App available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.

Part 2 of our Mastermind Expert Panel with Ally Machate + Tonya Kubo. Both biz specialists with a huge amount of Mastermind experience. Plus, deep knowledge of community + running a business. They're also both in one of my current Masterminds + we've worked together for years.  Excellent people to dig into what makes a Mastermind Group effective + more entertainingly, what makes one actually awful. We get into the importance of curation, the role of the facilitator + we share insights on how to get the most out of similar groups. Look for Part 1 - where we discussed why Mastermind groups work so well Book mentioned in this episode: Think and Grow Rich - Napoleon Hill Ally's Website:  www.thewritersally.com  Tonya's Facebook Community: The Secret to Thriving Online Communities Tonya on LinkedIn: linkedin.com/in/tonyakubo -- If you'd like my help with your Business go to www.lizscully.com/endlessClients ==== And don't forget to get your reading list of the 10 essential reads for every successful biz owner - these are the books Liz recommends almost on the daily to her strategy + Mastermind clients. This isn't your usual list of biz books, these answer the challenges you've actually got coming up right now. Helpful, quick to read and very timely. Click here lizscully.com/reading to get your book list

Send us a textIn this episode we talk with researcher & professor Dr. Enette Larson-Meyer about:Nutrient Assessment of the AthleteLow Energy AvailabilityCGMsDr. Enette Larson-Meyer, PhD, RD, CSSD, FACSM is currently a professor at Virginia Tech where she directs the Nutrition and Exercise Metabolism Laboratory and the Master of Science in Nutrition and Dietetics program. She is trained in  nutrition/dietetics and exercise science and her interests include energy and micronutrient metabolism, plant-based nutrition, and endocrine (non-diabetes) and metabolic disorders. Her research focuses on how nutrition influences the health and performance of active individuals at all stages of life and at all levels of performance. Recent research interests include healthy weight gain in athletes and the importance of micronutrient status—particularly iodine and vitamin D— in sports/exercise performance, disease prevention and general wellness. Enette has authored over 100 scientific articles and book chapters, is the author of “Plant-Based Sports Nutrition. Expert Fueling Strategies for Training, Recovery, and Performance” (Human Kinetics, 2020), and is an Associate Editor for Medicine & Science in Sports & Exercise and the Science and Medicine of Football. She served on the 2011 IOC Sports Nutrition Consensus Panel and the 2017 Expert Panel for Dietary Supplements and the High Performance Athlete and is currently a member of the International Testing Agency Health & Clinical Expert Advisory Group. Earlier in her career, Enette interned at the U.S. Olympic Training Center in Colorado Springs and served as the sports dietitian for the University of Alabama at Birmingham. Her personal interests include road cycling, flat water kayaking, Irish step dancing, resistance training, gardening, yoga, cooking and wine tasting. She is the mother of 3 athletic children, who consistently put her sports nutrition knowledge to the test.Please note that this podcast is created strictly for educational purposes and should never be used for medical diagnosis and treatment.***Connect w/ Dr. Enette Larson-Meyer: X: @enettemeyerrdWeb / Google ScholarMentioned:Nutrient Assessment of the Athlete2024 Compendium of Physical ActivitiesMORE NR New customers save 10% off all products on our website with the code NEWPOD10 If you would like to work with our practitioners, click here: https://nutritional-revolution.com/work-with-us/ Save 20% on all supplements at our trusted online source: https://us.fullscript.com/welcome/kchannell Join Nutritional Revolution's The Feed Club to get $20 off right away with an additional $20 Feed credit drop every 90 days.: https://thefeed.com/teams/nutritional-revolution Interested in blood testing? Use code NUTRITIONALREVOLUTION at InsideTracker for 20% off any test: store.insidetracker.com/nutritionalrevolution If you're interested in sponsoring Nutritional Revolution Podcast, shoot us an email at nutritionalrev@gmail.com.

Welcome to another live Q&A session from NeuroNoodle! In this episode, Pete Jansons hosts an expert panel, including Jay Gunkelman, Dr. Mari Swingle, Joy Lunt, Dr. Andrew Hill, Santiago Brand, Anthony Ramos, and John Mekrut. They dive deep into neurofeedback's impact on autism, ADHD, mental health, and brain training. Hear insightful discussions, real-time audience questions, and practical applications for neurofeedback therapy.

Today I'm inviting you out on a luxury yacht to swim in crystal clear coves, smell the scent of lavender, and enjoy a cocktail under the pink skies of sunset. We're setting out to explore the Dalmatian Islands off the coast of Croatia and enjoy all the culture, food, wine, and beauty they have to offer.  Our guests today are my friends in the region, Giorgio Surian, Mirela Rubic, and Alberto Dittadi. We chat about the culture in the islands, some really special experiences to be had, the history and landscape, and more.  Learn more at www.luxtravelinsider.com   Connect with me on Social: Instagram LinkedIn  

Summary Jim Himes (Website; X) joins Andrew (X; LinkedIn) to discuss the U.S. House Intelligence Committee. Jim has served as the U.S. representative for Connecticut's 4th congressional district since 2009.  What You'll Learn Intelligence The House Permanent Select Committee on Intelligence: Its role and operations The importance of bipartisan collaboration Transparency and accountability in intelligence  Congressman Himes' personal experiences during 9/11, its impact on his career in intelligence, and 9/11's impact on intelligence at large Reflections Public trust and earning confidence Partnership and cooperation And much, much more … Quotes of the Week “I get asked all the time, ‘Oh my gosh, you see all the threats. Do you sleep at night?' … Yes, I do see with particularly exquisite detail the threats against us. I also get to see the detail of the assets and the people that we deploy against those threats. And because I get to see with great detail the assets and the tools that we have to address those threats, yes, I do sleep at night. Not because they will ever be perfect, but because these are incredibly dedicated people, the technology is amazing, and it is commensurate with the threats out there.” -Jim Himes Resources  SURFACE SKIM *SpyCasts* Digital Innovation and the Next Frontier of Intelligence with Jennifer Ewbank (2024) The Future of OSINT and the Intelligence Community with Jason Barrett (2024) The Future of NATO with Leon Panetta and Expert Panel (2024) CIA Director, Defense Secretary, Gentleman with Leon Panetta (2024) DEEPER DIVE Books Sies, Lies, and Algorithms: The History and Future of American Intelligence, A. B. Zegart (Princeton University Press, 2022) The Secret World: A History of Intelligence, C. Andrew (Yale University Press, 2019) The First Congress: How James Madison, George Washington, and a Group of Extraordinary Men Invented the Government, F. M. Bordewich (Simon & Schuster, 2016) Primary Sources  House Intelligence Committee COVID-19 Report (2022) Unclassified Summary of the Second Interim Report on the Origins of the COVID-19 Pandemic (2022) House Intelligence Committee Report on Russian Active Measures (2018) Snowden Report (2016) The 9/11 Commission Report (2004)  H. Res. 658 (1977) *Wildcard Resource* One of Connecticut's very first representatives was a gentleman named Roger Sherman. Sherman is unique not only for being one of Jim's congressional predecessors but also because he is the only person to have signed all four great state papers of the United States.  These include: The Declaration of Independence, the Articles of Confederation, the Articles of Association, and the Constitution. As a bonus, he also signed the 1774 Petition to the King.  Learn more about your ad choices. Visit megaphone.fm/adchoices

This video features a panel discussion with three esteemed professionals from Jesse Brown VA Medical Center, discussing the importance of breast cancer screening for women veterans. Dr. Sarada Deshpande, Board Certified Internist and Women's Health Medical Director, Chasitie Levesque, Clinical Pharmacy Specialist, and Asya Brodsky, LCSW and Women Veteran Program Manager, share insights on the growing women veteran population, the healthcare services available to them, and how the VA is expanding its breast cancer screening efforts. Learn how women veterans can access comprehensive care, including screenings, mental health services, and reproductive care.

How do appraisals impact buyers and sellers in this shifting marketing? Angela sits down with two experts to find out: Mike Swaim, appraiser and co-owner of Swaim Appraisals, and Jenn Oliver, Senior Loan Consultant with New American Funding. They discuss how appraisals are going as the market shifts toward a balance between buyers and sellers and how buyer agent compensation changes impact appraisals and pricing.   Speakers: Angela Fisher (Agent Development Director) Mike Swaim (Appraiser) Jenn Oliver (Senior Loan Consultant)

John Solomon and Amanda Head sit down with Moms for Liberty Co-Founder Tiffany Justice to discuss Moms for Liberty Townhall at the Republican National Convention for a discussion on of empowering parents to take charge of their children's educations, on what steps can be taken at the state and local government level on the imperative issue of parental rights. Expert Panel with Louisiana Attorney General Liz Murrill, Missouri Attorney General Andrew Bailey, and West Virginia Attorney General Patrick Morrisey. To watch the special or see the daily show go to AmericasVoice.news each Monday through Friday at 6PM Eastern or watch any time at JustTheViews.com (http://JustTheViews.com/)See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

John Solomon and Amanda Head sit down with Moms for Liberty Co-Founder Tiffany Justice to discuss Moms for Liberty Townhall at the Republican National Convention for a discussion on empowering parents to take charge of their children's educations and how parents can take on the national establishment of woke teachers unions by lobbying Congress and their state legislatures on the issue of parental rights. Expert Panel with Wyoming GOP Rep. Harriet Hageman, GOP Florida Rep. Byron Donalds, GOP Wisconsin Sen. Ron Johnson. To watch the special or see the daily show go to AmericasVoice.news each Monday through Friday at 6PM Eastern or watch any time at JustTheViews.com (http://justtheviews.com/)See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.